The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
- Sponsor
- Peking Union Medical College Hospital
- Study ID
- NCT05170542
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Camrelizumab+S-1 — DRUGCamrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks.
Study Details
In this study, We investigated the efficacy and safty of camrelizumab combined with S-1 maintenance after first-line induction chemotherapy for GC. Patients without progressive disease after 4-6 weeks of first-line chemotherapy with SOX will be treated with camrelizumab combined with S-1.
Key Dates
- Start date
- Dec 24, 2021
- Status verified
- Dec 2021
- Primary completion
- Dec 24, 2025
- Completion
- Jan 24, 2026
Study Design
- Enrollment
- 42 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Camrelizumab+S-1
Primary Outcome Measure
Progression-Free Survival (PFS) [ Time Frame: From the start of randomization to a minimum of 42 months ]